Literature DB >> 12592315

24. Clinical and laboratory assessment of immunity.

James D Folds1, John L Schmitz.   

Abstract

Clinicians order specific laboratory tests and interpret laboratory data that will be useful in establishing a diagnosis of immunodeficiency, either inherited (primary) immunodeficiencies or acquired (secondary) immunodeficiencies. The clinical immunologic evaluation of patients for immunodeficiency proceeds in an orderly fashion, from screening tests to sophisticated tests. The medical history and physical examination of the patient frequently provide clues guiding the level of entry into this testing program. Specific tests have been designed to screen for the four basic mechanisms of host defense: Antibody, T cell, phagocyte, and complement. The clinical immunology laboratory is a powerful adjunct to the clinician in the initial evaluation of immunodeficiency disorders and in the design of more sophisticated testing for selected patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12592315     DOI: 10.1067/mai.2003.122

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  12 in total

1.  Patient-centred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists.

Authors:  E de Vries
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

2.  Early indicators of immunodeficiency in adults and children: protocols for screening for primary immunological defects.

Authors:  W A C Sewell; S Khan; P C Doré
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

Review 3.  Laboratory diagnosis of primary immunodeficiencies.

Authors:  Bradley A Locke; Trivikram Dasu; James W Verbsky
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

Review 4.  Nutritional Considerations for Healthy Aging and Reduction in Age-Related Chronic Disease.

Authors:  Julie Shlisky; David E Bloom; Amy R Beaudreault; Katherine L Tucker; Heather H Keller; Yvonne Freund-Levi; Roger A Fielding; Feon W Cheng; Gordon L Jensen; Dayong Wu; Simin N Meydani
Journal:  Adv Nutr       Date:  2017-01-17       Impact factor: 8.701

5.  Recognizing primary immune deficiency in clinical practice.

Authors:  Hale Yarmohammadi; Lissette Estrella; John Doucette; Charlotte Cunningham-Rundles
Journal:  Clin Vaccine Immunol       Date:  2006-03

6.  Robust antimicrobial photodynamic therapy with curcumin-poly (lactic-co-glycolic acid) nanoparticles against COVID-19: A preliminary in vitro study in Vero cell line as a model.

Authors:  Maryam Pourhajibagher; Maryam Azimi; Vahid Haddadi-Asl; Hanie Ahmadi; Mehrdad Gholamzad; Sara Ghorbanpour; Abbas Bahador
Journal:  Photodiagnosis Photodyn Ther       Date:  2021-04-07       Impact factor: 3.631

7.  Primary immunodeficiency in infection-prone children in southern Sweden: occurrence, clinical characteristics and immunological findings.

Authors:  Nicholas Brodszki; Göran Jönsson; Lillemor Skattum; Lennart Truedsson
Journal:  BMC Immunol       Date:  2014-08-14       Impact factor: 3.615

Review 8.  The Clinical Utility of Measuring IgG Subclass Immunoglobulins During Immunological Investigation for Suspected Primary Antibody Deficiencies.

Authors:  Antony R Parker; Markus Skold; David B Ramsden; J Gonzalo Ocejo-Vinyals; Marcos López-Hoyos; Stephen Harding
Journal:  Lab Med       Date:  2017-11-08

9.  Combination of lymphocyte number and function in evaluating host immunity.

Authors:  Ying Luo; Yalong Xie; Weijie Zhang; Qun Lin; Guoxing Tang; Shiji Wu; Min Huang; Botao Yin; Jin Huang; Wei Wei; Jing Yu; Hongyan Hou; Liyan Mao; Weiyong Liu; Feng Wang; Ziyong Sun
Journal:  Aging (Albany NY)       Date:  2019-12-20       Impact factor: 5.682

10.  Recurrent respiratory tract infections in children - analysis of immunological examinations.

Authors:  Agata Raniszewska; Elżbieta Górska; Iwona Kotuła; Anna Stelmaszczyk-Emmel; Katarzyna Popko; Olga Ciepiela
Journal:  Cent Eur J Immunol       Date:  2015-08-03       Impact factor: 2.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.